AHWhite on Nostr: Europe's EMEA recommends to refuse Leqembi, Eisai's "anti-Alzheimer's" antibody. It's ...
Europe's EMEA recommends to refuse Leqembi, Eisai's "anti-Alzheimer's" antibody. It's approved by the FDA in the US. I think the EMEA is making the right call. The clinical data and modest improvements (if any) are really not convincing imo.
https://www.ema.europa.eu/en/medicines/human/EPAR/leqembi#science
#neuroscience
Published at
2024-07-26 12:58:36Event JSON
{
"id": "87a98a3cf11ecb00645422f8e389067419cb2eebcb70b59c8dd5eaa55a2dadfe",
"pubkey": "c286c36b992f32efd68ab60584984572aaa82453d579f3b58aea5b15d1a1b2c5",
"created_at": 1721998716,
"kind": 1,
"tags": [
[
"t",
"science"
],
[
"t",
"neuroscience"
]
],
"content": "Europe's EMEA recommends to refuse Leqembi, Eisai's \"anti-Alzheimer's\" antibody. It's approved by the FDA in the US. I think the EMEA is making the right call. The clinical data and modest improvements (if any) are really not convincing imo.\n\nhttps://www.ema.europa.eu/en/medicines/human/EPAR/leqembi\n\n#science\n#neuroscience\n\n",
"sig": "1d92c918e0a40cb3f1bb840a4af69cc10060a838fae59c3fdf4c71d6904d6cb611dcab5364e48df179eb019e13b2bc7fe766d57e40cadaabd2fce1c11c3ced49"
}
